ProQR Therapeutics N.V.
PRQR
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentoā¦ read more
Healthcare
Biotechnology
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.22
Price+3.26%
$0.07
1Y
Price
Market Cap
$233.786m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in EUR.-624.1%
EBITDA Margin-658.3%
Net Profit Margin-556.3%
Free Cash Flow Margin-624.1%
EBITDA Margin-658.3%
Net Profit Margin-556.3%
Free Cash Flow MarginRevenue
$13.486m
-11.7%
1y CAGR+53.1%
3y CAGR+60.1%
5y CAGREarnings
-$45.708m
-12.8%
1y CAGR-19.2%
3y CAGR-0.3%
5y CAGREPS
-$0.44
-15.8%
1y CAGR-8.2%
3y CAGR+9.2%
5y CAGRBook Value
$37.637m
$99.137m
Assets$61.500m
Liabilities$13.701m
DebtDebt to Assets
13.8%
-0.3x
Debt to EBITDAFree Cash Flow
-$48.994m
+5.2%
1y CAGR-106.3%
3y CAGR-47.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company